Skip to content
The Lyme disease vaccine candidate developed by Pfizer and Valneva was “found to be more immunogenic” in pediatric patients than in adults in a […]
Pfizer-Valneva Lyme vaccine shows promising results in children Read More »
While Parkinson’s disease is still incurable, biotechnology, supported by good policy, offers the promise of better treatments, and perhaps an eventual cure. This is
Parkinson’s Awareness Month highlights hope of progress through research Read More »
Does the U.S. Food and Drug Administration (FDA) question the decision by the Centers for Medicaid and Medicare Services (CMS) to limit coverage of
Does the FDA question the Aduhelm decision? Read More »
The U.S. Food and Drug Administration (FDA) on Monday said it has expanded approval for Gilead Sciences Inc.’s Veklury (remdesivir) to include pediatric patients
Veklury becomes first FDA-approved COVID treatment for children under 12 Read More »
Nkarta today announced positive preliminary data in two Phase 1 clinical trials of its natural killer cell therapies to treat patients with advanced blood
Nkarta announces positive preliminary results with natural killer cell cancer therapies Read More »
Duke University scientists are working on a potential breast cancer vaccine using the innovative mRNA technology that enabled rapid development of COVID-19 vaccines, Fox
Duke researchers use mRNA to develop potential breast cancer vaccine Read More »
Everyone’s talking about pharmacy benefit managers (PBMs)—including the Federal Trade Commission (FTC)—but what exactly are PBMs and why do they matter in the context
What are PBMs, anyway? Read More »
“Unfortunately, people of African descent are significantly underrepresented in clinical trials, meaning that products and regimens approved based on data from people of other
BVGH AC³T is changing lives, one clinical trial at a time Read More »
A new study provides further evidence that hospitals—not manufacturers—often determine what patients and insurers pay for lifesaving cancer treatments. For patients with private insurance,
Hospitals mark up price of cancer drugs by as much as 630%, says study Read More »
Everyone in the U.S. over age 60 should get a second booster shot of their COVID-19 vaccine, Dr. Ashish K. Jha, a White House
White House COVID advisor recommends a second booster for those over 60 Read More »
